GeneDx launches prenatal whole genome sequencing test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care
January 7, 2026 8:30 AM ESTNew whole genome sequencing test delivers fast, comprehensive insights when fetal anomalies are identified, reinforcing GeneDxs commitment to enabling precise, fast, and actionable rare disease diagnosis at the earliest moment possible
GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GenomeDx Prenatal, whole genome sequencing (WGS) designed to deliver clear, reliable answers during one of the most critical moments in pregnancy care. The phenotype-informed, trio-based test is intended for pregnancies with fetal anomalies identified via ultrasound, enabling clinicians... More
